EFFECTIVENESS AND TOXICITY OF SECOND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE THERAPY FOR RELAPSED OR PROGRESSIVE MULTIPLE MYELOMA
(Abstract release date: 05/19/16)
EHA Library. El Fatmi R. 06/09/16; 135057; PB2157
Dr. Rym El Fatmi
Contributions
Contributions
Abstract
Abstract: PB2157
Type: Publication Only
Background
Multiple myeloma (MM) is still an incurable disease despite the introduction of novel therapy. Relapse or progression (R/P) following autologous stem cell transplantation is common. Therapeutic options may include novel agents often followed by second ASCT.
Aims
We aimed to evaluate the effectiveness and toxicity of salvage ASCT in R/P multiple myeloma.
Methods
We retrospectively analyzed the outcome of patients who underwent second autologous stem cell transplantation as salvage therapy for R/P MM, between February 2007 and February 2014.
Results
Thirty four patients underwent salvage ASCT. Conditioning regimen was melphalan 200 mg/m2(n=32) or 140mg/m2 (n=2). The median age was 54 years (36- 60 years) at first ASCT and 57 years (37- 63 years) at second ASCT. Twenty patients (59%) were men. Median duration of response after first ASCT was 28 months (4-61 months), 6 patients (17%) relapsed within the first year of ASCT. Twenty nine (85%) patients received a salvage therapy: Thalidomide- Dexamethasone (n=17), Bortezomib based (n=10), Lenalidomide-Dexamethasone (n=1) and Melphalan-Prednisone (n=1). Median interval between first and salvage ASCT was 37.6 months (9-72 months). Twenty one patients (72%) were at least in partial response before second ASCT. Non relapse mortality (NRM) was 9%. Response was assessable at 3 months post-ASCT in 30 patients: 25 patients (83%) achieved at least partial response, 4 had progressed disease and 1 stable disease. After salvage ASCT, 9 patients received thalidomide maintenance therapy. The median progression-free survival (PFS) after second ASCT was 12 months (0.7 – 35 months) and median overall survival (OS) was 21 months (0.7 -65.4 months).
Conclusion
Salvage ASCT is an effective therapeutic option for relapsed or progressive multiple myeloma although associated with a high NRM.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Multiple myeloma, Relapse
Type: Publication Only
Background
Multiple myeloma (MM) is still an incurable disease despite the introduction of novel therapy. Relapse or progression (R/P) following autologous stem cell transplantation is common. Therapeutic options may include novel agents often followed by second ASCT.
Aims
We aimed to evaluate the effectiveness and toxicity of salvage ASCT in R/P multiple myeloma.
Methods
We retrospectively analyzed the outcome of patients who underwent second autologous stem cell transplantation as salvage therapy for R/P MM, between February 2007 and February 2014.
Results
Thirty four patients underwent salvage ASCT. Conditioning regimen was melphalan 200 mg/m2(n=32) or 140mg/m2 (n=2). The median age was 54 years (36- 60 years) at first ASCT and 57 years (37- 63 years) at second ASCT. Twenty patients (59%) were men. Median duration of response after first ASCT was 28 months (4-61 months), 6 patients (17%) relapsed within the first year of ASCT. Twenty nine (85%) patients received a salvage therapy: Thalidomide- Dexamethasone (n=17), Bortezomib based (n=10), Lenalidomide-Dexamethasone (n=1) and Melphalan-Prednisone (n=1). Median interval between first and salvage ASCT was 37.6 months (9-72 months). Twenty one patients (72%) were at least in partial response before second ASCT. Non relapse mortality (NRM) was 9%. Response was assessable at 3 months post-ASCT in 30 patients: 25 patients (83%) achieved at least partial response, 4 had progressed disease and 1 stable disease. After salvage ASCT, 9 patients received thalidomide maintenance therapy. The median progression-free survival (PFS) after second ASCT was 12 months (0.7 – 35 months) and median overall survival (OS) was 21 months (0.7 -65.4 months).
Conclusion
Salvage ASCT is an effective therapeutic option for relapsed or progressive multiple myeloma although associated with a high NRM.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Multiple myeloma, Relapse
Abstract: PB2157
Type: Publication Only
Background
Multiple myeloma (MM) is still an incurable disease despite the introduction of novel therapy. Relapse or progression (R/P) following autologous stem cell transplantation is common. Therapeutic options may include novel agents often followed by second ASCT.
Aims
We aimed to evaluate the effectiveness and toxicity of salvage ASCT in R/P multiple myeloma.
Methods
We retrospectively analyzed the outcome of patients who underwent second autologous stem cell transplantation as salvage therapy for R/P MM, between February 2007 and February 2014.
Results
Thirty four patients underwent salvage ASCT. Conditioning regimen was melphalan 200 mg/m2(n=32) or 140mg/m2 (n=2). The median age was 54 years (36- 60 years) at first ASCT and 57 years (37- 63 years) at second ASCT. Twenty patients (59%) were men. Median duration of response after first ASCT was 28 months (4-61 months), 6 patients (17%) relapsed within the first year of ASCT. Twenty nine (85%) patients received a salvage therapy: Thalidomide- Dexamethasone (n=17), Bortezomib based (n=10), Lenalidomide-Dexamethasone (n=1) and Melphalan-Prednisone (n=1). Median interval between first and salvage ASCT was 37.6 months (9-72 months). Twenty one patients (72%) were at least in partial response before second ASCT. Non relapse mortality (NRM) was 9%. Response was assessable at 3 months post-ASCT in 30 patients: 25 patients (83%) achieved at least partial response, 4 had progressed disease and 1 stable disease. After salvage ASCT, 9 patients received thalidomide maintenance therapy. The median progression-free survival (PFS) after second ASCT was 12 months (0.7 – 35 months) and median overall survival (OS) was 21 months (0.7 -65.4 months).
Conclusion
Salvage ASCT is an effective therapeutic option for relapsed or progressive multiple myeloma although associated with a high NRM.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Multiple myeloma, Relapse
Type: Publication Only
Background
Multiple myeloma (MM) is still an incurable disease despite the introduction of novel therapy. Relapse or progression (R/P) following autologous stem cell transplantation is common. Therapeutic options may include novel agents often followed by second ASCT.
Aims
We aimed to evaluate the effectiveness and toxicity of salvage ASCT in R/P multiple myeloma.
Methods
We retrospectively analyzed the outcome of patients who underwent second autologous stem cell transplantation as salvage therapy for R/P MM, between February 2007 and February 2014.
Results
Thirty four patients underwent salvage ASCT. Conditioning regimen was melphalan 200 mg/m2(n=32) or 140mg/m2 (n=2). The median age was 54 years (36- 60 years) at first ASCT and 57 years (37- 63 years) at second ASCT. Twenty patients (59%) were men. Median duration of response after first ASCT was 28 months (4-61 months), 6 patients (17%) relapsed within the first year of ASCT. Twenty nine (85%) patients received a salvage therapy: Thalidomide- Dexamethasone (n=17), Bortezomib based (n=10), Lenalidomide-Dexamethasone (n=1) and Melphalan-Prednisone (n=1). Median interval between first and salvage ASCT was 37.6 months (9-72 months). Twenty one patients (72%) were at least in partial response before second ASCT. Non relapse mortality (NRM) was 9%. Response was assessable at 3 months post-ASCT in 30 patients: 25 patients (83%) achieved at least partial response, 4 had progressed disease and 1 stable disease. After salvage ASCT, 9 patients received thalidomide maintenance therapy. The median progression-free survival (PFS) after second ASCT was 12 months (0.7 – 35 months) and median overall survival (OS) was 21 months (0.7 -65.4 months).
Conclusion
Salvage ASCT is an effective therapeutic option for relapsed or progressive multiple myeloma although associated with a high NRM.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Multiple myeloma, Relapse
{{ help_message }}
{{filter}}